11,603 AbbVie Inc. $ABBV Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,059 shares of the company’s stock after selling 11,603 shares during the period. AbbVie comprises about 0.8% of Harbour Investments Inc.’s holdings, making the stock its 22nd largest position. Harbour Investments Inc.’s holdings in AbbVie were worth $54,949,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. IFG Advisory LLC grew its stake in AbbVie by 0.3% in the 3rd quarter. IFG Advisory LLC now owns 43,135 shares of the company’s stock valued at $11,284,000 after acquiring an additional 150 shares during the last quarter. Riverpoint Wealth Management Holdings LLC increased its holdings in AbbVie by 0.7% during the 3rd quarter. Riverpoint Wealth Management Holdings LLC now owns 8,769 shares of the company’s stock valued at $2,294,000 after acquiring an additional 60 shares in the last quarter. Optas LLC raised its position in AbbVie by 1.5% during the third quarter. Optas LLC now owns 7,627 shares of the company’s stock worth $1,995,000 after acquiring an additional 114 shares during the last quarter. AlTi Global Inc. raised its position in AbbVie by 48.8% during the third quarter. AlTi Global Inc. now owns 26,662 shares of the company’s stock worth $6,975,000 after acquiring an additional 8,745 shares during the last quarter. Finally, Phoenix Financial Ltd. raised its position in AbbVie by 10.1% during the third quarter. Phoenix Financial Ltd. now owns 52,244 shares of the company’s stock worth $13,667,000 after acquiring an additional 4,803 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on ABBV shares. Royal Bank Of Canada upped their price target on shares of AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. Argus raised their price objective on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Leerink Partners lifted their price objective on AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a research report on Monday, November 2nd. BNP Paribas Exane lifted their price objective on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, BMO Capital Markets set a $315.00 target price on AbbVie in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $297.46.

Read Our Latest Research Report on AbbVie

AbbVie Stock Performance

AbbVie stock traded up $0.73 during midday trading on Friday, reaching $295.18. 3,259,920 shares of the company were exchanged, compared to its average volume of 5,279,493. The firm’s 50-day simple moving average is $275.51 and its 200-day simple moving average is $240.91. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The company has a market capitalization of $521.76 billion, a price-to-earnings ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the prior year, the firm earned $1.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts forecast that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 125.30%.

Insider Buying and Selling at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Latest AbbVie News

Investors following ABBV have been watching these news items:

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.